Patents by Inventor Mark Barvian

Mark Barvian has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 2-(pyridin-2-ylamino)-pyrido[2,3, d]pyrimidin-7-ones
    Patent number: 7456168
    Abstract: The present invention provides substituted 2-aminopyridines useful in treating cell proliferative disorders. The novel compounds of the present invention are potent inhibitors of cyclin-dependent kinases 4 (cdk4).
    Type: Grant
    Filed: April 11, 2007
    Date of Patent: November 25, 2008
    Assignee: Warner-Lambert Company
    Inventors: Mark Barvian, Richard John Booth, John Quin, III, Joseph Thomas Repine, Derek J. Sheehan, Peter Laurence Toogood, Scott Norman Vanderwel, Hairong Zhou
  • 2-(PYRIDIN-2-YLAMINO)-PYRIDO [2,3 D]PYRIMIDIN-7-ONES
    Publication number: 20070179118
    Abstract: The present invention provides substituted 2-aminopyridines useful in treating cell proliferative disorders. The novel compounds of the present invention are potent inhibitors of cyclin-dependent kinases 4 (cdk4).
    Type: Application
    Filed: April 11, 2007
    Publication date: August 2, 2007
    Inventors: Mark Barvian, Richard Booth, John Quin, Joseph Repine, Derek Sheehan, Peter Toogood, Scott Vanderwel, Hairong Zhou
  • 2-(pyridin-2-ylamino)-pyrido [2,3-d]pyrimidin-7-ones
    Patent number: 7208489
    Abstract: The present invention provides substituted 2-aminopyridines useful in treating cell proliferative disorders.
    Type: Grant
    Filed: January 28, 2005
    Date of Patent: April 24, 2007
    Assignee: Warner-Lambert Company
    Inventors: Mark Barvian, Richard John Booth, John Quin, III, Joseph Thomas Repine, Derek J. Sheehan, Peter Laurence Toogood, Scott Norman Vanderwel, Hairong Zhou
  • HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis
    Patent number: 7179918
    Abstract: Compounds of the formula: where the formula variables are as defined herein, are disclosed that advantageously inhibit or block the biological activity of the HIV protease. These compounds, as well as pharmaceutical compositions containing these compounds, are useful for treating patients or hosts infected with the HIV virus. Intermediates and synthetic methods for preparing such compounds are also described.
    Type: Grant
    Filed: June 11, 2002
    Date of Patent: February 20, 2007
    Assignee: Agouron Pharmaceuticals, Inc.
    Inventors: Stacie S. Canan Koch, Therese N. Alexander, Benjamin J. Burke, Tanya M. Jewell, David J. Kucera, Maria Angelica Linton, Lennert J. Mitchell, Jr., Siegfried H. Reich, Donald J. Skalitzky, John H. Tatlock, Michael D. Varney, Scott C. Virgil, Stephen E. Webber, Stephen T. Worland, Mark Barvian, Gary Bolton, Frederick Earl Boyer, Jr., Jeffrey J. Machak, Tod Holler, Sean T. Murphy, Michael Melnick, Vara Prasad Josyula
  • HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis
    Publication number: 20070021354
    Abstract: Compounds of the formula: where the formula variables are as defined herein, are disclosed that advantageously inhibit or block the biological activity of the HIV protease. These compounds, as well as pharmaceutical compositions containing these compounds, are useful for treating patients or hosts infected with the HIV virus. Intermediates and synthetic methods for preparing such compounds are also described.
    Type: Application
    Filed: June 9, 2006
    Publication date: January 25, 2007
    Inventors: Stacie Canan Koch, Therese Alexander, Benjamin Burke, Tanya Jewell, David Kucera, Maria Linton, Lennert Mitchell, Siegfried Reich, Donald Skalitzky, John Tatlock, Michael Varney, Scott Virgil, Stephen Webber, Stephen Worland, Mark Barvian, Gary Bolton, Frederick Boyer, Jeffrey Machak, Tod Holler, Sean Murphy, Michael Melnick, Vara Josyula
  • HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis
    Publication number: 20050250707
    Abstract: Compounds of the formula: where the formula variables are as defined herein, are disclosed that advantageously inhibit or block the biological activity of the HIV protease. These compounds, as well as pharmaceutical compositions containing these compounds, are useful for treating patients or hosts infected with the HIV virus. Intermediates and synthetic methods for preparing such compounds are also described.
    Type: Application
    Filed: June 20, 2005
    Publication date: November 10, 2005
    Inventors: Stacie Canan Koch, Therese Alexander, Benjamin Burke, Tanya Jewell, David Kucera, Maria Linton, Lennert Mitchell, Siegfried Reich, Donald Skalitzky, John Tatlock, Michael Varney, Scott Virgil, Stephen Webber, Stephen Worland, Mark Barvian, Gary Bolton, Frederick Boyer, Jeffrey Machak, Tod Holler, Sean Murphy, Michael Melnick, Vara Josyula
  • HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis
    Patent number: 6953858
    Abstract: Compounds of the formula: where the formula variables are as defined herein, are disclosed that advantageously inhibit or block the biological activity of the HIV protease. These compounds, as well as pharmaceutical compositions containing these compounds, are useful for treating patients or hosts infected with the HIV virus. Intermediates and synthetic methods for preparing such compounds are also described.
    Type: Grant
    Filed: June 11, 2002
    Date of Patent: October 11, 2005
    Assignee: Agouron Pharmaceuticals, Inc.
    Inventors: Stacie S. Canan Koch, Therese N. Alexander, Mark Barvian, Gary Bolton, Frederick Earl Boyer, Jr., Benjamin J. Burke, Tod Holler, Tanya M. Jewell, Vara Prasad Josyula, David J. Kucera, Maria Angelica Linton, Jeffrey J. Machak, Lennert J. Mitchell, Jr., Sean T. Murphy, Siegfried H. Reich, Donald J. Skalitzky, John H. Tatlock, Michael D. Varney, Scott C. Virgil, Stephen E. Webber, Stephen T. Worland, Michael Melnick
  • 2-(Pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones
    Patent number: 6936612
    Abstract: The present invention provides substituted 2-aminopyridines useful in treating cell proliferative disorders.
    Type: Grant
    Filed: January 16, 2003
    Date of Patent: August 30, 2005
    Assignee: Warner-Lambert Company
    Inventors: Mark Barvian, Richard John Booth, John Quin, III, Joseph Thomas Repine, Derek J. Sheehan, Peter Laurence Toogood, Scott Norman Vanderwel, Hairong Zhou
  • 2-(Pyridin-3-ylamino)-pyrido[2,3-D]pyrimidin-7-ones
    Publication number: 20050182078
    Abstract: This invention provides compounds of formula I: wherein R1, R2, R3, R4, and X1 are as defined in the specification. The 2-(pyridin-3-ylamino)-pyrido[2,3-d]pyrimidin-7-one compounds of formula I, which are inhibitors of cyclin-dependent kinases 2 and 4 (CDK2 and CDK4), are useful in treating cell proliferative disorders.
    Type: Application
    Filed: February 16, 2005
    Publication date: August 18, 2005
    Inventors: Mark Barvian, Peter Toogood, Scott VanderWel
  • 2-(Pyridin-2-ylamino)-pyrido [2,3-D]pyrimidin-7-ones
    Publication number: 20050137214
    Abstract: The present invention provides substituted 2-aminopyridines useful in treating cell proliferative disorders. The novel compounds of the present invention are potent inhibitors of cyclin-dependent kinases 4 (cdk4).
    Type: Application
    Filed: January 28, 2005
    Publication date: June 23, 2005
    Inventors: Mark Barvian, Richard Booth, John Quin, Joseph Repine, Derek Sheehan, Peter Toogood, Scott Vanderwel, Hairong Zhou
  • HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis
    Publication number: 20030225071
    Abstract: Compounds of the formula: 1
    Type: Application
    Filed: June 11, 2002
    Publication date: December 4, 2003
    Inventors: Stacie S. Canan Koch, Therese N. Alexander, Mark Barvian, Gary Bolton, Fredrick E. Boyer, Benjamin J. Burke, Tod Holler, Tanya M. Jewell, Vara Prasad Josyula, David J. Kucera, Maria A. Linton, Jeffrey J. Machak, Lennert J. Mitchell, Sean T. Murphy, Siegfried H. Reich, Donald J. Skalitzky, John H. Tatlock, Michael D. Varney, Scott C. Virgil, Stephen E. Webber, Stephen T. Worland, Michael Melnick
  • HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis
    Publication number: 20030153507
    Abstract: Compounds of the formula: 1
    Type: Application
    Filed: June 11, 2002
    Publication date: August 14, 2003
    Inventors: Stacie S. Canan-Koch, Therese N. Alexander, Mark Barvian, Gary Bolton, Frederick E. Boyer, Benjamin J. Burke, Tod Holler, Tanya M. Jewell, Vara Prasad Josyula, David J. Kucera, Maria A. Linton, Jeffrey J. Machak, Lennert J. Mitchell, Sean T. Murphy, Siegfried H. Reich, Donald J. Skalitzky, John H. Tatlock, Michael D. Varney, Scott C. Virgil, Stephen E. Webber, Stephen T. Worland, Michael Melnick
  • 2-(Pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones
    Publication number: 20030149001
    Abstract: The present invention provides substituted 2-aminopyridines useful in treating cell proliferative disorders. The novel compounds of the present invention are potent inhibitors of cyclin-dependent kinases 4 (cdk4).
    Type: Application
    Filed: January 16, 2003
    Publication date: August 7, 2003
    Inventors: Mark Barvian, Richard John Booth, John Ouin, Joseph Thomas Repine, Derek J. Sheehan, Peter Laurence Toogood, Scott Norman Vanderwel, Hairong Zhou
  • 2-(pyridin-2-ylamino)-pyrido[2,3-D]pyrimidin-7-ones
    Patent number: RE47739
    Abstract: The present invention provides substituted 2-aminopyridines useful in treating cell proliferative disorders.
    Type: Grant
    Filed: July 27, 2018
    Date of Patent: November 26, 2019
    Assignee: Warner-Lambert Company LLC
    Inventors: Mark Barvian, Richard John Booth, John Quinn, III, Joseph Thomas Repine, Derek J. Sheehan, Peter Lawrence Toogood, Scott Norman Vanderwel, Hairong Zhou